JPS624370B2 - - Google Patents
Info
- Publication number
- JPS624370B2 JPS624370B2 JP51157338A JP15733876A JPS624370B2 JP S624370 B2 JPS624370 B2 JP S624370B2 JP 51157338 A JP51157338 A JP 51157338A JP 15733876 A JP15733876 A JP 15733876A JP S624370 B2 JPS624370 B2 JP S624370B2
- Authority
- JP
- Japan
- Prior art keywords
- varicella
- virus
- vaccine
- zoster virus
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 claims description 26
- 229960005486 vaccine Drugs 0.000 claims description 24
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000007514 Herpes zoster Diseases 0.000 description 5
- 201000006082 Chickenpox Diseases 0.000 description 4
- 206010046980 Varicella Diseases 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000394 Varicella Zoster Encephalitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960001201 live attenuated varicella Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/821—Drug, bio-affecting and body treating compositions involving temperature-sensitive mutant virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/644,787 US4008317A (en) | 1975-12-29 | 1975-12-29 | Varicella-zoster virus vaccine and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5282721A JPS5282721A (en) | 1977-07-11 |
| JPS624370B2 true JPS624370B2 (OSRAM) | 1987-01-30 |
Family
ID=24586321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15733876A Granted JPS5282721A (en) | 1975-12-29 | 1976-12-24 | Production of chcken poxx herpes zoster virus vaccine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4008317A (OSRAM) |
| JP (1) | JPS5282721A (OSRAM) |
| BE (1) | BE849897A (OSRAM) |
| DE (1) | DE2655691C2 (OSRAM) |
| FR (1) | FR2336944A1 (OSRAM) |
| GB (1) | GB1565830A (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043847A4 (en) * | 1980-01-25 | 1982-07-06 | Wistar Inst | HIGHLY ATTENUED CHICKENPOX VIRUS VACCINE AND PRODUCTION THEREOF. |
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| US4714678A (en) * | 1982-10-13 | 1987-12-22 | Smithkline-Rit | Temperature sensitive strain of bovine viral diarrhoea virus |
| IT1213254B (it) * | 1984-12-06 | 1989-12-14 | Boehringer Biochemia Srl | Metodo diagnostico per la valutazione di parametri clinici mediante prelievo diretto dimateriali biologici e dispositivoper la sua attuazione. |
| ES2150906T3 (es) | 1990-10-04 | 2000-12-16 | Res Corp Technologies Inc | Antigeno del virus varicella-zoster. |
| US5824319A (en) * | 1990-10-04 | 1998-10-20 | Research Corporation Technologies, Inc. | Varicella-zoster virus antigen |
| JP4562812B2 (ja) * | 1992-07-17 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法 |
| US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
| US7666082B2 (en) * | 2004-05-07 | 2010-02-23 | Gamelogic Inc. | Method and apparatus for conducting a game of chance |
| US10350289B2 (en) | 2013-09-05 | 2019-07-16 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
-
1975
- 1975-12-29 US US05/644,787 patent/US4008317A/en not_active Expired - Lifetime
-
1976
- 1976-12-08 DE DE2655691A patent/DE2655691C2/de not_active Expired
- 1976-12-22 GB GB53537/76A patent/GB1565830A/en not_active Expired
- 1976-12-24 JP JP15733876A patent/JPS5282721A/ja active Granted
- 1976-12-28 BE BE173669A patent/BE849897A/xx not_active IP Right Cessation
- 1976-12-29 FR FR7639469A patent/FR2336944A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| US4008317A (en) | 1977-02-15 |
| JPS5282721A (en) | 1977-07-11 |
| GB1565830A (en) | 1980-04-23 |
| FR2336944B1 (OSRAM) | 1980-07-18 |
| FR2336944A1 (fr) | 1977-07-29 |
| BE849897A (fr) | 1977-06-28 |
| DE2655691C2 (de) | 1985-08-14 |
| DE2655691A1 (de) | 1977-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabin | Present status of attenuated live-virus poliomyelitis vaccine | |
| US6120773A (en) | Recombinant herpes simplex viruses vaccines and methods | |
| Bustamante et al. | Herpes simplex virus infection in the immunocompromised cancer patient. | |
| Morice et al. | Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects | |
| Meignier et al. | Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus | |
| JPH07505891A (ja) | 弱毒化呼吸器合胞体ウイルスワクチン組成物 | |
| JPS624370B2 (OSRAM) | ||
| JPH09504803A (ja) | ポックスウイルス成分の組み合わせにもとづく類属免疫誘導剤、その製造方法および薬剤としての使用 | |
| Michalek et al. | Virulence of Streptococcus mutans: biochemical and pathogenic characteristics of mutant isolates | |
| Gordon et al. | HSV-1 thymidine kinase promotes virulence and latency in the mouse. | |
| US4315914A (en) | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof | |
| US4731245A (en) | Vaccine, antigen and antibody for treating microorganisms of the MCLS-type streptococcus sanguis | |
| Pichini et al. | DNA mapping of paired varicella-zoster virus isolates from patients with shingles | |
| US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
| EP0413637A1 (en) | Attenuated live hepatitis A vaccine (H2 Strain) and its method of preparation | |
| CN110743007B (zh) | 一种联合疫苗及其制备方法、应用 | |
| JP7747527B2 (ja) | ブタ繁殖および呼吸障害症候群ワクチンウイルス | |
| US4569840A (en) | Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis | |
| Benson et al. | Vaccination of infants with living attenuated measles vaccine (Edmonston strain) with and without gamma-globulin | |
| Holland et al. | Herpesvirus and enteric viral infections in bone marrow transplantation clinical presentations, pathogenesis, and therapeutic strategies | |
| McCrumb Jr et al. | Clinical trials with living attenuated measles virus vaccines | |
| JPH07509244A (ja) | 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法 | |
| Caudill et al. | Recovery of a latent HSV-1 thymidine kinase negative strain following iontophoresis and co-cultivation in the ocularly-infected rabbit model | |
| EP0119025B1 (en) | Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis | |
| Pascuzzi | Poliomyelitis and the postpolio syndrome |